Renovis is a biopharmaceutical company that seeks to improve the lives of patients suffering from neurological disease with novel drugs that renew, restore, and repair the nervous system. The Company is developing REN-1654, a Phase II drug for neuropathic pain, and REN-213, a drug for post-operative pain that will enter Phase I later in 2003. Renovis will be entitled to future milestones and royalties in connection with the successful development of Ceroviveā„¢, which is in pivotal Phase III clinical trials for acute ischemic stroke and is licensed to AstraZeneca. In addition to its clinical candidates, Renovis has preclinical programs, discovery research, and specialized chemistry currently focused in the areas of pain and neuroinflammation.

Renovis is now a wholly owned subsidiary of Evotec, AG.


Date Type Amount Investors Valuation
08/03/03 Series E 45M Alta Partners, Capital Funds, CDIB Bioscience Ventures, Easton Capital Partners, Flagship Ventures, HBM Bioventures, HealthCap, Invus Group, MDS Capital, Skyline Ventures, Venrock Associates Unknown


Marlene Perry (Board member)

Jeffrey Farrow (Board member)

Bruce Carter (Board member)

Dushyant Pathak (Board member)

Michael Kelly (Board member)

View more details about all 12 people at Renovis